Ignite Creation Date:
2025-12-25 @ 4:46 AM
Ignite Modification Date:
2025-12-26 @ 3:47 AM
Study NCT ID:
NCT07047118
Status:
RECRUITING
Last Update Posted:
2025-12-03
First Post:
2025-05-20
Is NOT Gene Therapy:
False
Has Adverse Events:
False
Brief Title:
A Study of JSB462 (Luxdegalutamide) Plus Lutetium (177Lu) Vipivotide Tetraxetan in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC)
Sponsor:
Novartis Pharmaceuticals
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2025-07-03
Start Date Type:
ACTUAL
Primary Completion Date:
2028-01-07
Primary Completion Date Type:
ESTIMATED
Completion Date:
2028-11-04
Completion Date Type:
ESTIMATED
First Submit Date:
2025-05-20
First Submit QC Date:
None
Study First Post Date:
2025-07-02
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2025-12-02
Last Update Post Date:
2025-12-03
Last Update Post Date Type:
ESTIMATED